HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Severer phenotype in Unverricht-Lundborg disease (EPM1) patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutation in the CSTB gene.

AbstractBACKGROUND/AIMS:
Unverricht-Lundborg disease (EPM1) is caused by mutations in the cystatin B (CSTB) gene. Most patients are homozygous for the expanded dodecamer repeat mutation alleles, but 9 other EPM1-associated mutations have also been identified. We describe the clinical, cognitive and imaging characteristics of 5 Finnish EPM1 patients who are compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutations.
METHODS:
Five compound heterozygous patients and 21 patients homozygous for the expansion mutation, participating in an ongoing nationwide clinical and molecular genetics study, were evaluated using the Unified Myoclonus Rating Scale test and comprehensive neuropsychological testing. All patients underwent MR imaging. The MR data were also compared with those of 24 healthy control subjects.
RESULTS:
Age at onset of symptoms was significantly lower in the compound heterozygotes than in the homozygous EPM1 patients. They also had severer myoclonus and drug-resistant tonic-clonic seizures. Moreover, they had lower cognitive performance. In MRI a voxel-based morphometry analysis of primary and premotor cortex, supplementary motor cortex and thalami revealed gray matter volume loss when compared with the healthy controls, similar to patients homozygous for the expansion mutation.
CONCLUSION:
Patients compound heterozygous for the dodecamer repeat expansion and the c.202C>T mutations seem to have a severer form of EPM1 than patients homozygous for the expansion mutation. These findings have implications for counseling of EPM1 patients with different genetic defects.
AuthorsPäivi Koskenkorva, Jelena Hyppönen, Marja Aikiä, Esa Mervaala, Tuula Kiviranta, Kai Eriksson, Anna-Elina Lehesjoki, Ritva Vanninen, Reetta Kälviäinen
JournalNeuro-degenerative diseases (Neurodegener Dis) Vol. 8 Issue 6 Pg. 515-22 ( 2011) ISSN: 1660-2862 [Electronic] Switzerland
PMID21757863 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 S. Karger AG, Basel.
Chemical References
  • Anticonvulsants
  • CSTB protein, human
  • Cystatin B
Topics
  • Adolescent
  • Adult
  • Alleles
  • Anticonvulsants (therapeutic use)
  • Cystatin B (genetics)
  • Disease Progression
  • Electroencephalography
  • Epilepsy, Tonic-Clonic (drug therapy, etiology)
  • Exons (genetics)
  • Female
  • Genotype
  • Humans
  • Image Processing, Computer-Assisted
  • Intelligence Tests
  • Magnetic Resonance Imaging
  • Male
  • Mutation (genetics, physiology)
  • Neuropsychological Tests
  • Phenotype
  • Repetitive Sequences, Amino Acid
  • Unverricht-Lundborg Syndrome (genetics, pathology)
  • Verbal Learning
  • Walking
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: